Table 3.

Meta-analysis between the MTHFR rs1801133 polymorphism and CAD risk after excluding the studies with heterogeneity

Comparisons	Ethnicity	OR	95% CI	P heterogeneity	P OR
Allelic model (T vs C)	Total	1.04	1.01–1.07	0.12	0.01
	Male	1.04	0.94–1.14	0.13	0.48
	Female	1.04	0.93–1.16	0.80	0.53
	Caucasian	1.03	1.00–1.06	0.32	0.07
	Asian	1.11	1.04–1.18	0.32	< 0.01
	African	0.94	0.78–1.13	0.11	0.50
	Other ethnicity	0.97	0.83–1.14	0.13	0.74
Additive model (TT vs CC)	Total	1.12	1.05–1.19	0.09	< 0.01
	Male	1.07	0.91–1.27	0.23	0.42
	Female	1.02	0.79–1.31	0.82	0.87
	Caucasian	1.08	1.01–1.16	0.57	0.03
	Asian	1.28	1.12–1.46	0.05	< 0.01
	African	0.79	0.50–1.26	0.26	0.32
	Other ethnicity	1.23	0.91–1.66	0.10	0.17
Dominant model (TT + CT vs CC)	Total	1.04	1.00–1.07	0.14	0.05
	Male	1.04	0.94–1.15	0.16	0.44
	Female	1.07	0.91–1.25	0.51	0.42
	Caucasian	1.01	0.97–1.05	0.61	0.56
	Asian	1.15	1.05–1.25	0.14	< 0.01
	African	1.01	0.81–1.26	0.07	0.94
	Other ethnicity	1.04	0.86–1.26	0.10	0.67
Recessive model (TT vs CT + CC)	Total	1.12	1.06–1.18	0.13	< 0.01
	Male	1.15	0.99–1.33	0.05	0.06
	Female	0.95	0.77–1.17	0.76	0.62
	Caucasian	1.07	1.01–1.14	0.68	0.03
	Asian	1.28	1.14–1.43	0.06	< 0.01
	African	0.78	0.52–1.18	0.29	0.24
	Other ethnicity	1.22	0.93–1.60	0.18	0.16

MTHFR 5,10-methylenetetrahydrofolate reductase gene, CAD coronary artery disease, OR odds ratio, 95% CI 95% confidence interval